Compared to NAFLD patients, NASH patients exhibit reduced levels of FXR, SHP, and NTCP proteins, and FXR plays a protective role in the progression from NAFLD to NASH (Aguilar-Olivos et al., 2015). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.